

**Supplementary Table 1.** Baseline Characteristics of Participants By Age at Randomization

Characteristic	Age < 65 At Randomization (N=6776)	Aged ≥65 At Randomization (N=3475)
Female sex (N, %)	2722, 40.2%	1230, 25.4%
Racial Minority (N, %)	2671, 39.4%	1187, 34.2%
High School Graduate (N, %)	5898, 87.1%	2825, 81.4%
Time Since Diagnosis of Diabetes (median)	9.97 +/- 7.09 (9.0)	12.57 +/- 8.68 (10.0)
Previous cardiovascular event (N, %)	2224, 32.8%	1385, 40.0%
Previous congestive heart failure (N, %)	276, 4.1%	218, 6.3%
Weight (kg)	95.8 +/- 19.0	90.1 +/- 17.4
Body Mass Index (kg/m <sup>2</sup> )	32.9 +/- 5.5	31.2 +/- 5.2
Waist Circumference (cm)	107.5 +/- 14.0	105.7 +/- 13.6
Systolic Blood Pressure (mm)	135.3 +/- 16.7	137.9 +/- 17.5
Diastolic Blood Pressure (mm)	76.8 +/- 10.3	71.8 +/- 10.5
A1C (%) (median)	8.4 +/- 1.1 (8.2)	8.2 +/- 0.9 (8.0)
Fasting Serum Glucose (mg/dl)	178.8 +/- 58.0	169.9 +/- 52.8
LDL-C (mg/dl)	107.0 +/- 34.7	101.6 +/- 32.0
HDL-C, Women (mg/dl)	46.6 +/- 12.4	47.8 +/- 12.9
HDL-C, Men (mg/dl)	38.2 +/- 9.5	39.3 +/- 9.8
Total Cholesterol (mg/dl)	186.7 +/- 43.0	178.0 +/- 39.1
Triglyceride (mg/dl)	200.4 +/- 164.6	174.2 +/- 117.5
Potassium (mg/dl)	4.5 +/- 0.6	4.5 +/- 0.5
Serum Creatinine (mg/dl)	0.9 +/- 0.2	1.0 +/- 0.2
Functional Limitations		
Some Mobility Limitation, (N, %)	1852, 27.7%	1065, 31.1%
Some Activity Limitation, (N, %)	374, 5.58%	128, 3.73%
Some Mobility or Activity Limitation (N, %)	1922, 28.8%	1093, 32.0%

p-value for differences between groups < 0.001 for all characteristics except HDL-C in Women (p=0.005)

SUPPLEMENTARY DATA

**Supplementary Table 2.** Medication Use By Baseline Age Before the Transition Date (February 5<sup>th</sup> 2008)\*

Variable	Intensive Glycemia <sup>†</sup>		Standard Glycemia <sup>†</sup>	
	Middle Aged	Older	Middle Aged	Older
<b>Glucose Lowering Medications:</b>				
Metformin (%)	2694 (79.3)	1153 (66.6)	2475 (73.2)	1058 (60.7)
Any Secretagogue (%)	2169 (63.9)	1000 (57.7)	1889 (55.9)	927 (53.2)
Glimepiride (%)	1620 (47.7)	694 (40.1)	1673 (49.5)	811 (46.5)
Repaglinide (%)	857 (25.2)	430 (24.8)	330 (9.8)	159 (9.1)
Any TZD (%)	1936 (57.0)	849 (49.0)	1077 (31.9)	414 (23.8)
Rosiglitazone (%)	1609 (47.4)	685 (39.6)	944 (27.9)	348 (20.0)
Pioglitazone (%)	328 (9.7)	166 (9.6)	133 (3.9)	66 (3.8)
α Glucosidase Inhibitor (%)	455 (13.4)	210 (12.1)	136 (4.0)	48 (2.8)
Incretin (%)	494 (14.6)	168 (9.7)	155 (4.6)	35 (2.0)
Exenatide (%)	274 (8.1)	66 (3.8)	100 (3.0)	19 (1.1)
Any Insulin (%)	2491 (73.4)	1241 (71.7)	1814 (53.7)	901 (51.7)
Insulin Dose (units/kg)	0.74 ± 0.57	0.63 ± 0.44	0.68 ± 0.48	0.60 ± 0.42
Any Bolus Insulin (%)	1492 (43.9)	750 (43.3)	791 (23.4)	378 (21.7)
Bolus Dose (units/kg)	0.35 ± 0.30	0.31 ± 0.23	0.37 ± 0.29	0.31 ± 0.24
<b>Classes of Medications Without Insulin:</b>				
1-2 Classes (%)	274 (8.1)	190 (11.0)	1005 (29.7)	617 (35.4)
3 Classes (%)	415 (12.2)	205 (11.8)	415 (12.3)	145 (8.3)
4-5 Classes (%)	182 (5.4)	74 (4.3)	30 (0.9)	5 (0.3)
<b>Classes of Medications With Insulin:</b>				
0 Classes (%)	195 (5.7)	181 (10.5)	324 (9.6)	244 (14.0)
1-2 Classes (%)	1339 (39.4)	747 (43.1)	1200 (35.5)	580 (33.3)
3 Classes (%)	763 (22.5)	261 (15.1)	269 (8.0)	71 (4.1)
4-5 Classes (%)	194 (5.7)	52 (3.0)	21 (0.6)	6 (0.3)
<b>Non-Glycemia Medications:</b>				
Antihypertensive (%)	2871 (84.5)	1541 (89.0)	2925 (86.5)	1580 (90.7)
Angiotensin-converting-enzyme inhibitor (%)	1735 (51.1)	906 (52.3)	1843 (54.5)	937 (53.8)
Aspirin (%)	2009 (59.2)	1011 (58.4)	1990 (58.9)	1013 (58.1)
Beta-Blocker (%)	1162 (34.2)	705 (40.7)	1277 (37.8)	721 (41.4)
Statin (%)	2515 (74.1)	1314 (75.9)	2509 (74.2)	1324 (76.0)

For each medication, we provide the number of participants ever prescribed the medication and the percent that this represents (in parentheses).

SUPPLEMENTARY DATA

**Supplementary Figure 1.** Plotted points represent median A1C levels obtained for participants attending each four month visit. Blue lines represent the standard glycemia arm and red lines represent the intensive arm. Dashed lines correspond to the older group ( $\geq 65$  years) and solid lines correspond to the middle-aged subgroup ( $< 65$  years).

